“It barely touches your heart rate.”

Incretin and multi-agonist compounds can nudge resting heart rate upward — it's one of the known, watched effects. In the main retatrutide trial, with its heavier participants, the change at a low 1 mg dose was small enough to wave off: under a single beat per minute on average.

But an earlier-phase study in a leaner, lighter cohort gave the same 1 mg dose and recorded an average rise of around +10 bpm. Same milligrams, same molecule — roughly a fourteen-fold difference in the cardiovascular response. The most likely explanation is the simplest one: in a smaller body, a fixed dose is a larger effective exposure, and the body responds accordingly.

The general lesson is bigger than heart rate. 'Well tolerated' is always a statement about the specific population that was studied, and tolerability data from a heavier trial group can quietly understate what a smaller person will feel — not just on heart rate, but on nausea, on how hard the appetite suppression hits, on everything dose-dependent.

This is the practical case for starting under the quoted range if you're lean, and for actually tracking your resting heart rate for the first few weeks rather than assuming the trial's reassuring number is yours.